B2M and neoplasm: Additionally, combination therapies (such as oncolytic viruses/bempegaldesleukin combined with ICIs), personalized neoantigen tumor vaccines, optimized CAR-T therapy (using gene editing technology to knock out B2M), NK cell therapy, radiotherapy, fecal microbiota transplantation, and cytokine therapy also provide promising approaches to reverse immune resistance induced by B2M mutation.